MedPath

Is treatment with emollients always beneficial? Comparative biophysical and molecularbiological studies of the skinbarrier function in patients with atopic dermatitis, ichtyosis vulgaris and x-linked ichtyosis.

Conditions
Patients with Atopic Dermatitis, Ichtyosis vulgaris and X-linked Ichtyosis
Registration Number
EUCTR2009-010609-35-SE
Lead Sponsor
Department of Medical Sciences, Dermatology and venerology, Uppsala University, Uppsala Sweden
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Patients with atopic dermatitis, ichtyosis vulgaris and x-linked ichtyosis. 18-65 yrs of age
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Any other concomittant skin disease. Pregnancy.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To achieve better knowledge about the cause of the impaired skinbarrier function in patients with atopic dermatitis, ichtyosis vulgaris and x-linked ichtyosis. <br>;Secondary Objective: To achieve more knowledge about the effects of emollients on this impaired barrier function, and about which ingredients in emollients that have beneficial or maybe negative effects on the barrier function in these patients.<br>To study if the effects of the different emollients are correlated to the different genotypes in the filaggring gene and a gene coding for steroid sulphatase.<br>;Primary end point(s): To evaluate the effect of 4 weeks daily treatment with emollients on the skin barrier function in patients with impaired barrierfunction.<br> + see E.2.1
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath